Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
about
Type-II NADH Dehydrogenase (NDH-2): a promising therapeutic target for antitubercular and antibacterial drug discovery.Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.Bedaquiline: Fallible Hope Against Drug Resistant Tuberculosis.
P2860
Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Health outcomes of bedaquiline ...... elected high burden countries.
@ast
Health outcomes of bedaquiline ...... elected high burden countries.
@en
type
label
Health outcomes of bedaquiline ...... elected high burden countries.
@ast
Health outcomes of bedaquiline ...... elected high burden countries.
@en
prefLabel
Health outcomes of bedaquiline ...... elected high burden countries.
@ast
Health outcomes of bedaquiline ...... elected high burden countries.
@en
P2093
P2860
P1476
Health outcomes of bedaquiline ...... selected high burden countries
@en
P2093
Antoine C El Khoury
Caitlin Smare
Chrispin Kambili
Xiaoyan Lu
P2860
P2888
P356
10.1186/S12913-016-1931-3
P577
2017-01-26T00:00:00Z
P6179
1074214076